Erasca (ERAS) Other Non-Current Assets (2020 - 2026)
Erasca's (ERAS) quarterly Other Non-Current Assets came in at $408000.0 in Q1 2026, down 84.4% YoY from $2.6 million in Q1 2025, and down 71.92% on a QoQ basis from $1.5 million in Q4 2025.
Erasca (ERAS) Other Non-Current Assets (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Other Non-Current Assets data on file, last reported at $408000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 84.4% year-over-year to $408000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408000.0 (down 84.4% YoY) and the FY2025 annual result came in at $1.5 million, up 256.13% from the prior year.
- Other Non-Current Assets eased to $408000.0 in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $5.2 million in Q2 2023 to a low of $408000.0 in Q1 2022.
- A 5-year average of $1.9 million and a median of $408000.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 1085.29% — and 2024, when it sank 91.56%.
- Tracing ERAS's Other Non-Current Assets over 5 years: stood at $408000.0 in 2022, then changed by 0.0% to $408000.0 in 2023, then changed by 0.0% to $408000.0 in 2024, then soared by 256.13% to $1.5 million in 2025, then sank by 71.92% to $408000.0 in 2026.
- The last three Other Non-Current Assets figures came in at $408000.0 (Q1 2026), $1.5 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Erasca | 6.43 Bn | 6.16 Bn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Mar 31, 2026 | 408,000.00 |
| Dec 31, 2025 | 1.45 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 408,000.00 |
| Mar 31, 2025 | 2.62 Mn |
| Dec 31, 2024 | 408,000.00 |
| Sep 30, 2024 | 408,000.00 |
| Jun 30, 2024 | 3.96 Mn |
| Mar 31, 2024 | 408,000.00 |
| Dec 31, 2023 | 408,000.00 |
| Sep 30, 2023 | 4.39 Mn |
| Jun 30, 2023 | 5.25 Mn |
| Mar 31, 2023 | 4.84 Mn |
| Dec 31, 2022 | 408,000.00 |
| Sep 30, 2022 | 408,000.00 |
| Jun 30, 2022 | 4.71 Mn |
| Mar 31, 2022 | 408,000.00 |
| Dec 31, 2021 | 408,000.00 |
| Sep 30, 2021 | 408,000.00 |